Angiotensin II receptor antagonists. Potential in elderly patients with cardiovascular disease

Drugs and Aging

Volumn 10, Issue 6, 1997, Pages 421-434

  Burrell, Louise M ^a   Johnston, Colin I ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; CANDESARTAN HEXETIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE; IRBESARTAN; LOSARTAN; RENIN; VALSARTAN;

AGED; AGING; ANGIONEUROTIC EDEMA; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; COUGHING; DRUG EFFICACY; DRUG TOLERABILITY; DYSGEUSIA; ESSENTIAL HYPERTENSION; HEART DISEASE; HEART FAILURE; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOTENSION; KIDNEY DISEASE; MORBIDITY; MORTALITY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK FACTOR; TREATMENT OUTCOME; VERTIGO;

EID: 0030982693     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-199710060-00003     Document Type: Review

References (65)

1. World Health Organization. Hypertension control. Geneva: WHO, 1996
2. Amery A, Birkenhager W, Brixko P, et al. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet 1985; 1: 1349-54
3. MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. BMJ 1992; 304: 405-12
4. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA 1991; 265: 3255-64
5. Dahlof B, Lindholm LH, Hansson L, et al. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP Hypertension). Lancet 1991; 338: 1281-5
6. Johannesson M, Dahlof B, Lindholm LH, et al. The cost-effectiveness of treating hypertension in elderly people - an analysis of the Swedish Trial in Old Patients with Hypertension (STOP Hypertension). J Intern Med 1993; 234: 317-23
7. National High Blood Pressure Education Program Working Group. National High Blood Pressure Education Program Working Group report on hypertension in the elderly. Hypertension 1994; 23: 275-85
8. Byyny RL. Hypertension in the elderly. In: Laragh JH, Brenner BM, editors. Hypertension: pathophysiology, diagnosis, and management. New York: Raven Press, 1995: 227-51
9. Abdelrahman AM, Burrell LM, Johnston CI. Blockade of the renin-angiotensin system at different sites: effect on renin, angiotensin and aldosterone. J Hypertens 1993; 11 Suppl. 3: S23-6
10. Johnston CI, Burrell LM. Evolution of blockade of the reninangiotensin system. J Hum Hypertens 1995; 9: 375-80
11. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe heart failure. N Engl J Med 1987; 316: 1429-35
12. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992; 327: 685-91
13. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. Lancet 1994; 343: 1115-22
14. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors with heart failure. Lancet 1993; 342: 821-8
15. Burrell LM, Johnston CI. Beyond ACE inhibition: new developments in drug therapy for hypertension. Med J Aust 1995; 162: 659-61
16. Johnston CI. Angiotensin receptor antagonists: focus on losartan. Lancet 1995; 346: 1403-7
17. Bauer JH, Reams GP. The angiotensin II type 1 receptor antagonists. Arch Intern Med 1995; 155: 1361-8
18. Timmermans PB, Wong PC, Chiu AT, et al. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 1993; 45: 205-51
19. Goldberg AI, Dunlay MC, Sweet CS. Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension. Am J Cardiol 1995; 75: 793-5
20. Israili ZH, Hall WD. ACE inhibitors: differential use in elderly patients with hypertension. Drugs Aging 1995; 7: 355-71
21. Chan JC, Critchley JA, Lappe JT, et al. Randomised, double-blind, parallel study of the anti-hypertensive efficacy and safety of losartan potassium compared with felodipine ER in elderly patients with mild to moderate hypertension. J Hum Hypertens 1995; 9: 765-71
22. Nagano M, Higaki J, Mikami H, et al. Role of the renin-angio-tensin system in hypertension in the elderly. Blood Press Suppl 1994; 5: 130-3
23. Grossman E, Peleg E, Carroll J, et al. Hemodynamic and humoral effects of the angiotensin II antagonist losartan in essential hypertension. Am J Hypertens 1994; 7: 1041-4
24. Nolan L, O'Malley K. Prescribing for the elderly, part 1: sensitivity of the elderly to adverse drug reactions. J Am Geriatr Soc 1988; 36: 142-9
25. Lo M-W, Goldberg MR, McCrea JB, et al. Pharmacokinetics of losartan, an angiotensin II receptor antagonist and its active metabolite EXP 3174 in humans. Clin Pharmacol Ther 1995; 58: 611-9
26. Ogihara T, Nagano M, Mikami H, et al. Effects of the angiotensin II receptor antagonist, TCV-116, on blood pressure and the renin-angiotensin system in healthy subjects. Clin Ther 1994; 16: 74-86
27. Holwerda NJ, Fogari R, Angeli P, et al. Valsartan, a new angio-tensin II antagonist for the treatment of essential hyperten-sion: efficacy and safety compared with placebo and enalapril. J Hypertens 1996; 14: 1147-51
28. Stearns RA, Chakravarty PK, Chen R, et al. Biotransformation of losartan to its active carboxylic acid metabolite in human liver microsomes: role of cytochrome P4502C and 3A subfamily members. Drug Metab Dispos 1995; 23 (2): 207-15
29. Pitt B, Chang P, Timmermans PB. Angiotensin II receptor antagonists in heart failure: rationale and design of the evaluation of losartan in the elderly (ELITE) trial. Cardiovasc Drugs Ther 1995; 9: 693-700
30. Shand BI, Gilchrist NL, Nicholls MG, et al. Effect of losartan on haematology and haemorheology in elderly patients with essential hypertension: a pilot study. J Hum Hypertens 1995; 9: 233-5
31. Weber MA, Byyny RL, Pratt JH, et al. Blood pressure effects of the angiotensin II receptor blocker, losartan. Arch Intern Med 1995; 155: 405-11
32. Tsunoda K, Abe K, Hagino T, et al. Hypotensive effect of losartan, a nonpeptide angiotensin II receptor antagonist, in essential hypertension. Am J Hypertens 1993; 6: 28-32
33. Gradman AH, Arcuri KE, Goldberg AI, et al. A randomized, placebo-controlled, double-blind, parallel study of various doses of losartan potassium compared with enalapril maleate in patients with essential hypertension. Hypertension 1995; 25: 1345-50
34. Tikkanen I, Omvik P, Jensen H. Comparison of the angiotensin II antagonist, losartan with the angiotensin converting enzyme inhibitor enalapril in patients with essential hypertension. J Hypertens 1995; 13: 1343-51
35. Mallion J-M, Bradstreet DC, Makris L, et al. Antihypertensive efficacy and tolerability of once daily losartan potassium compared with captopril in patients with mild to moderate hypertension. J Hypertens 1995; 13 Suppl. I: S35-41
36. Dahlof B, Keller SE, Makris L, et al. Efficacy and tolerability of losartan potassium and atenolol in patients with mild to moderate essential hypertension. Am J Hypertens 1995; 8: 578-83
37. MacKay JH, Arcuri KE, Goldberg AI, et al. Losartan and low-dose hydrochlorothiazide in patients with essential hypertension: a double-blind, placebo-controlled trial of concomitant administration compared with individual components. Arch Intern Med 1996; 156: 278-85
38. Soffer BA, Wright Jr JT, Pratt JH, et al. Effects of losartan on a background of hydrochlorothiazide in patients with hypertension. Hypertension 1995; 26: 112-7
39. Weir MR, Elkins M, Liss C, et al. Efficacy, tolerability, and quality of life of losartan, alone or with hydrochlorothiazide, versus nifedipine GITS in patients with essential hypertension. Clin Ther 1996; 18 (3): 1-18
40. Ogihara T, Arakawa K, Iimura O, et al. Open clinical studies on a new angiotensin II receptor antagonist, TCV 116. J Hypertens 1994; 12 Suppl.: S35-8
41. van den Meiracker AH, Admiraal PJ, Janssen JA, et al. Hemodynamic and biochemical effects of the AT1 receptor antaconist irbesarlan in hypertension. Hypertension 1995; 25: 22-9
42. Dunlay MC, Fitzpatrick V, Chrysant S, et al. Losartan potassium as initial therapy in patients with severe hypertension. J Hum Hypertens 1995; 9: 861-7
43. Ruff D, Gazdick LP, Berman R, et al. Comparative effects of combination therapy with either losartan potassium, an angiotensin II receptor antagonist, or enalapril maleate for the treatment of severe hypertension. J Hypertens 1996; 14: 263-70
44. Gottlieb SS, Dickstein K, Fleck E, et al. Hemodynamic and neurohormonal effects of the angiotensin II antagonist losartan in patients with congestive heart failure. Circulation 1993; 88: 1602-9
45. Crozier I, Ikram H, Awan N, et al. Losartan in heart failure: hemodynamic effects and tolerability. Losartan Hemodynamic Study Group, Circulation 1995; 91 (3): 691-7
46. Dickstein K, Gottlieb S, Fleck E, et al. Hemodynamic and neurohumoral effects of the angiotensin II antagonist losartan in patients with heart failure. J Hypertens 1994; 12 Suppl.: S31-5
47. Burrell LM. Risk-benefit assessment of losartan potassium in the treatment of hypertension. Drug Saf 1997; 16 (1): 56-65
48. Goa KL, Wagstaff AJ. Losartan potassium: a review of its pharmacology, clinical efficacy and tolerability in the management of hypertension. Drugs 1996; 51 (5): 820-45
49. Lewis EJ, Hunsicker LG, Bain RP, et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993; 329: 1456-62
50. Burnier M, Rutschmann B, Nussberger J. Salt-dependent renal effects of an angiotensin II antagonist in healthy subjects. Hypertension 1993; 22: 339-47
51. Gansevoort RT, de Zeeuw D, Shahinfar S, et al. Effects of the angiotensin II antagonist losartan in hypertensive patients with renal disease. J Hypertens 1994; 12 Suppl. 2: S37-42
52. Gansevoort RT, de Zeeuw D, de Jong PE. Is the antiproteinuric effect of ACF inhibition mediated by interference in the renin-angiotensin system? Kidney Int 1994; 45: 861-7
53. Kawabata M, Takabatake T, Ohta H, et al. Effects of an angiotensin II receptor antagonist, TCV-116, on renal haemodynamics in essential hypertension. Blood Press Suppl 1994; 5: 117-21
54. Kasiske BL, Kalil RS, Ma JZ, et al. Effect of antihypertensive therapy on the kidney in patients with diabetes: a meta-regression analysis. Ann Intern Med 1993; 118: 129-38
55. Ichikawa I. Will angiotensin II receptor antagonists be renoprotective in humans? Kidney Int 1996; 50: 684-92
56. Lacourciere Y, Brunner H, Irwin R, et al. Effects of modulators of the renin-angiotensin-aldosterone system on cough. Losartan Cough Study Group. J Hypertens 1994; 12: 1387-93
57. Acker CG, Greenberg A. Angioedema induced by the angiotensin II blocker losartan [letter]. N Engl J Med 1995; 333: 1572
58. Schlienger RG, Saxer M, Haefeli W. Reversible ageusia associated with losartan. Lancet 1996; 347: 471-2
59. Sweet CS, Bradstreet DC, Berman RS, et al. Pharmacodynamic activity of intravenous E-3174, an angiotensin II antagonist, in patients with essential hypertension. Am J Hypertens 1994; 7: 1035-40
60. Goldberg MR, Bradstreet TE, McWilliams EJ, et al. Biochemical effects of losartan, a nonpeptide angiotensin II receptor antagonist, on the renin-angiotensin-aldosterone system in hypertensive patients. Hypertension 1995; 25: 37-46
61. Moan A, Risanger T, Eide I, et al. The effect of angiotensin II receptor blockade on insulin sensitivity and sympathetic nervous system activity in primary hypertension. Blood Press 1994; 3 (3): 185-8
62. Saine DR, Ahrens ER. Renal impairment associated with losartan [lelter]. Ann Intern Med 1996; 124 (8): 775
63. Kjeldsen SE, Omvik P. Losartan and the LIFE-study: antihypertensive treatment with AT1-receptor antagonist. Tidsskr Nor Laegeforen 1996; 116: 504-7
64. Urata H, Boehm KD, Philip A, et al. Cellular localization and regional distribution of an angiotensin II-forming chymase in the heart. J Clin Invest 1993; 91: 1269-81
65. Pitt B, Segal R, Martinez FA, et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997; 349: 747-52